Thermo Fisher Scientific introduces Gibco CTS DynaXS Single Use Bioreactor
New Gibco™ CTS™ DynaXS™ single use bioreactor platform enables controlled, cGMP‑ready cell expansion from development through commercialization
6 May 2026Product news
Thermo Fisher Scientific has launched the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, an integrated cell therapy manufacturing platform designed to help cell therapy developers and manufacturers scale production with precise control, flexibility and regulatory readiness from process development through clinical and commercial manufacturing.
Developed for use within Thermo Fisher’s Cell Therapy Systems portfolio, the CTS DynaXS bioreactor supports the transition from early clinical programs to full-scale commercial cell therapy production across oncology, autoimmune and other emerging therapeutic areas.
Addressing the need for scalable cell therapy manufacturing
Cell therapy manufacturers are under increasing pressure to move rapidly from early clinical success to commercial manufacturing while managing growing process complexity. As cell therapies expand beyond oncology into autoimmune and additional indications, developers require robust, scalable and cGMP-ready platforms that can support consistent cell expansion across multiple stages of development.
The Gibco CTS DynaXS Single Use Bioreactor is purpose-built to address these challenges by providing a dedicated expansion platform that supports scalable, cGMP-ready cell production from small-scale process development through clinical and commercial manufacturing.
Integrated single-use bioreactor platform for end-to-end scale-up
The CTS DynaXS bioreactor combines a stirred-tank, single-use bioreactor design with flexible operating parameters and an automation-ready architecture. This configuration enables cell therapy developers to efficiently scale from small process development batches to larger commercial runs while maintaining consistent quality and process control.
By supporting a wide range of operating conditions, the platform is designed to help manufacturers optimize cell expansion processes, reduce manual interventions and support reproducible performance as they move through development, clinical and commercial stages.
The Gibco CTS DynaXS Single Use Bioreactor integrates within Thermo Fisher Scientific’s broader Cell Therapy Systems portfolio. This integration provides unified technical support, modular workflow design and streamlined regulatory documentation to support cell therapy developers as they progress from early clinical programs to full-scale manufacturing.
By aligning with Thermo Fisher’s existing cell therapy solutions, the CTS DynaXS platform helps simplify technology adoption, supports regulatory readiness and enables a more cohesive approach to end-to-end cell therapy manufacturing.
Simplifying workflows and accelerating commercial readiness
This integrated approach to cell therapy manufacturing is designed to simplify workflows, reduce scale-up variability and accelerate the path to commercial readiness. By providing a scalable, cGMP-ready bioreactor platform with automation-ready features and unified support, Thermo Fisher Scientific aims to help customers bring life-changing cell therapies to patients faster.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
How does the Gibco CTS DynaXS Single Use Bioreactor support scalable cell therapy manufacturing from process development to commercial production?
The Gibco CTS DynaXS Single Use Bioreactor is designed as a dedicated expansion platform that supports scalable, cGMP-ready cell production from small-scale process development through clinical and commercial manufacturing. Its stirred-tank, single-use bioreactor design, combined with flexible operating parameters and an automation-ready architecture, enables cell therapy developers and manufacturers to efficiently scale from early clinical programs to full-scale commercial runs while maintaining consistent quality, process control and regulatory readiness.
What benefits does the CTS DynaXS bioreactor offer cell therapy developers working in oncology, autoimmune and other emerging therapeutic areas?
The CTS DynaXS bioreactor helps cell therapy developers in oncology, autoimmune and other emerging therapeutic areas address the pressure to move rapidly from early clinical success to commercial manufacturing while managing increasing process complexity.
By providing a robust, scalable and cGMP-ready platform that supports consistent cell expansion across multiple stages of development, the system is designed to optimize cell expansion processes, reduce manual interventions, support reproducible performance and ultimately accelerate the path to commercial readiness for life-changing cell therapies.
How does integration of the Gibco CTS DynaXS Single Use Bioreactor within Thermo Fisher Scientific’s Cell Therapy Systems portfolio enhance regulatory readiness and workflow efficiency?
The Gibco CTS DynaXS Single Use Bioreactor integrates within Thermo Fisher Scientific’s broader Cell Therapy Systems portfolio, providing unified technical support, modular workflow design and streamlined regulatory documentation. This integration simplifies technology adoption and supports regulatory readiness by offering a cohesive, end-to-end cell therapy manufacturing approach.
As a result, workflows are simplified, scale-up variability is reduced and cell therapy manufacturers are better positioned to progress efficiently from early clinical programs to full-scale commercial manufacturing.